vs

Side-by-side financial comparison of Legence Corp. (LGN) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Legence Corp. is the larger business by last-quarter revenue ($708.0M vs $622.0M, roughly 1.1× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs -0.1%, a 34.5% gap on every dollar of revenue. On growth, Legence Corp. posted the faster year-over-year revenue change (26.2% vs 4.8%).

Legence Corp is a leading sustainable building and decarbonization solution provider. It delivers energy efficiency optimization, building automation design, renewable energy integration, and low-carbon retrofit services for commercial, industrial, and institutional clients, with core operations across North America to help customers cut costs and reduce carbon footprints.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

LGN vs RPRX — Head-to-Head

Bigger by revenue
LGN
LGN
1.1× larger
LGN
$708.0M
$622.0M
RPRX
Growing faster (revenue YoY)
LGN
LGN
+21.5% gap
LGN
26.2%
4.8%
RPRX
Higher net margin
RPRX
RPRX
34.5% more per $
RPRX
34.4%
-0.1%
LGN

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LGN
LGN
RPRX
RPRX
Revenue
$708.0M
$622.0M
Net Profit
$-576.0K
$214.2M
Gross Margin
20.9%
Operating Margin
5.3%
62.4%
Net Margin
-0.1%
34.4%
Revenue YoY
26.2%
4.8%
Net Profit YoY
46.8%
2.9%
EPS (diluted)
$-0.02
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LGN
LGN
RPRX
RPRX
Q4 25
$622.0M
Q3 25
$708.0M
$609.3M
Q2 25
$578.7M
Q1 25
$568.2M
Q4 24
$593.6M
Q3 24
$560.8M
$564.7M
Q2 24
$537.3M
Q1 24
$568.0M
Net Profit
LGN
LGN
RPRX
RPRX
Q4 25
$214.2M
Q3 25
$-576.0K
$288.2M
Q2 25
$30.2M
Q1 25
$238.3M
Q4 24
$208.2M
Q3 24
$-1.1M
$544.0M
Q2 24
$102.0M
Q1 24
$4.8M
Gross Margin
LGN
LGN
RPRX
RPRX
Q4 25
Q3 25
20.9%
Q2 25
Q1 25
Q4 24
Q3 24
21.1%
Q2 24
Q1 24
Operating Margin
LGN
LGN
RPRX
RPRX
Q4 25
62.4%
Q3 25
5.3%
70.1%
Q2 25
36.3%
Q1 25
94.0%
Q4 24
60.9%
Q3 24
4.8%
Q2 24
50.2%
Q1 24
-13.0%
Net Margin
LGN
LGN
RPRX
RPRX
Q4 25
34.4%
Q3 25
-0.1%
47.3%
Q2 25
5.2%
Q1 25
41.9%
Q4 24
35.1%
Q3 24
-0.2%
96.3%
Q2 24
19.0%
Q1 24
0.8%
EPS (diluted)
LGN
LGN
RPRX
RPRX
Q4 25
$0.49
Q3 25
$-0.02
$0.67
Q2 25
$0.07
Q1 25
$0.55
Q4 24
$0.46
Q3 24
$1.21
Q2 24
$0.23
Q1 24
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LGN
LGN
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$176.0M
$618.7M
Total DebtLower is stronger
$812.6M
$9.0B
Stockholders' EquityBook value
$387.9M
$9.7B
Total Assets
$2.6B
$19.6B
Debt / EquityLower = less leverage
2.10×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LGN
LGN
RPRX
RPRX
Q4 25
$618.7M
Q3 25
$176.0M
$938.9M
Q2 25
$631.9M
Q1 25
$1.1B
Q4 24
$929.0M
Q3 24
$950.1M
Q2 24
$1.8B
Q1 24
$843.0M
Total Debt
LGN
LGN
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$812.6M
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
LGN
LGN
RPRX
RPRX
Q4 25
$9.7B
Q3 25
$387.9M
$9.6B
Q2 25
$9.5B
Q1 25
$9.8B
Q4 24
$10.3B
Q3 24
$10.3B
Q2 24
$9.8B
Q1 24
$9.9B
Total Assets
LGN
LGN
RPRX
RPRX
Q4 25
$19.6B
Q3 25
$2.6B
$19.3B
Q2 25
$18.3B
Q1 25
$17.6B
Q4 24
$18.2B
Q3 24
$18.0B
Q2 24
$17.7B
Q1 24
$16.1B
Debt / Equity
LGN
LGN
RPRX
RPRX
Q4 25
0.92×
Q3 25
2.10×
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LGN
LGN
RPRX
RPRX
Operating Cash FlowLast quarter
$162.1M
$827.1M
Free Cash FlowOCF − Capex
$137.4M
FCF MarginFCF / Revenue
19.4%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LGN
LGN
RPRX
RPRX
Q4 25
$827.1M
Q3 25
$162.1M
$702.6M
Q2 25
$364.0M
Q1 25
$596.1M
Q4 24
$742.5M
Q3 24
$703.6M
Q2 24
$658.2M
Q1 24
$664.6M
Free Cash Flow
LGN
LGN
RPRX
RPRX
Q4 25
Q3 25
$137.4M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
LGN
LGN
RPRX
RPRX
Q4 25
Q3 25
19.4%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
LGN
LGN
RPRX
RPRX
Q4 25
Q3 25
3.5%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
LGN
LGN
RPRX
RPRX
Q4 25
3.86×
Q3 25
2.44×
Q2 25
12.06×
Q1 25
2.50×
Q4 24
3.57×
Q3 24
1.29×
Q2 24
6.45×
Q1 24
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LGN
LGN

Installation And Fabrication$408.7M58%
Engineering And Design$110.9M16%
Program And Project Management$101.2M14%
Maintenance And Service$87.1M12%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons